Hemosiderin deposits in chronic graft-vs.-host disease related myopathy
Martin Schmidt-Hieber1, Ali Fuat Okuducu, Gisela Stoltenburg
1Medizinische Klinik III (Hämatologie, Onkologie und Transfusionsmedizin), Charité- Campus, Benjamin Franklin, Hindenburgdamm, Berlin, Germany. martin.schmidt-hieber@charite.de
Insights
Chronic graft-vs.-host disease (cGVHD) can cause rare muscle issues. This case highlights unusual hemosiderin and lipofuscin deposits in skeletal muscle, suggesting a new cGVHD manifestation.
Area of Science:
- Hematology
- Immunology
- Neurology
Background:
- Chronic graft-vs.-host disease (cGVHD) affects 20-50% of allogeneic stem cell transplant survivors.
- Common cGVHD manifestations include skin, liver, lung, and systemic wasting syndromes.
- Polymyositis/myopathy are rare cGVHD complications, with few reported cases.
Observation:
- A 56-year-old male developed progressive muscular weakness and inability to walk post-allogeneic SCT.
- Muscle biopsy revealed perifascicular atrophy with hemosiderin and lipofuscin deposits.
- Elevated ferritin levels were noted, but standard muscle enzymes were normal.
Findings:
- This case presents a unique combination of hemosiderin and lipofuscin accumulation in skeletal muscle within cGVHD.
- Such deposits have not been previously reported in the skeletal muscle of cGVHD patients.
- Deferoxamine treatment was ineffective in improving the patient's condition.
Implications:
- This finding expands the spectrum of rare neuromuscular manifestations of cGVHD.
- It suggests a potential role for iron and pigment deposition in cGVHD-associated myopathy.
- Further research is needed to understand the pathogenesis and explore potential therapeutic strategies for this rare complication.
Abstract:
Chronic graft-vs.-host disease (cGVHD) occurs in 20-50% of patients who survive for at least 100 d after allogeneic stem cell transplantation (SCT). cGVHD includes scleroderma-like skin changes, chronic cholangitis, obstructive lung disease and general wasting syndrome. Polymyositis or myopathy are rare manifestations of cGVHD with approximately 40 reported cases. Polymyositis accompanied by hemosiderin deposits in cGVHD has been reported only once, and there are no reports on lipofuscin deposits in skeletal muscle cells in cGVHD. We report here on a 56-yr-old male who underwent allogeneic SCT in 1999 for osteomyelofibrosis and progressive hematopoietic insufficiency. In February 2004, the patient was hospitalized for progressive muscular weakness with loss of the ability to walk. Laboratory tests demonstrated normal values for serum creatine kinase, aldolase and lactic dehydrogenase; the ferritin level was highly elevated. The femoral muscle biopsy showed mostly perifascicular atrophy as well as numerous subsarcolemmal hemosiderin and lipofuscin deposits. Intravenous administration of the chelating agent deferoxamine was ineffective. Three weeks later the patient died of aspiration pneumonia. Interestingly, autopsy disclosed moderate hemosiderin deposits in the liver, the organ usually involved in hemosiderosis.
Related Concept Videos
Myasthenia Gravis ll: Pathophysiology
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myocarditis I: Introduction
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy


